SAN FRANCISCO, May 21 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN) today announced that additional clinical results from a Phase 1-2 clinical trial involving 140 men with advanced prostate cancer evaluating MDV3100, a next-generation androgen receptor antagonist, will be presented in an oral session at the American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Fla.
Oral Abstract Session: Genitourinary (Prostate) Cancer Abstract Title: "Antitumor Activity of MDV3100 in a Phase 1-2 Study of Castration-Resistant Prostate Cancer (CRPC)" (Abstract #5011) Presentation Date/Time: Saturday, May 30, at 4:15 p.m. ET Presenter: Dr. Howard Scher, principal investigator, chief of the Genitourinary Oncology Service and the D. Wayne Calloway Chair in Urologic Oncology at Memorial Sloan-Kettering Cancer Center in New York Location: Level 3, Chapin Theater W320
Additionally, this abstract was selected by ASCO for inclusion in the Best of ASCO(R) program, an educational initiative covering highlights from the ASCO Annual Meeting to increase global access to cutting-edge science.
Medivation recently received written permission from the U.S. Food and Drug Administration to begin a pivotal Phase 3 trial of MDV3100 in patients with advanced prostate cancer. The primary endpoint of the trial will be overall survival.
About Prostate Cancer
Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer and it is the second leading cause of cancer death amongst men after lung cancer.(i) In 2009, an estimated 192,280 new cases are expected to be diagnosed and approximately 27,360 men are expected to die from the disease. Castration-resistant prostate cancer (CRPC) is defined as prostate cancer that continues to grow despite all standard-of-care hormonal (anti-androgen) therapies. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.
Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer Inc to develop and commercialize Dimebon for the treatment of Alzheimer's and Huntington's diseases. With Pfizer, the Company is conducting a broad Dimebon clinical development program, including a pivotal and confirmatory Phase 3 trial, known as the CONNECTION study, in patients with mild-to-moderate Alzheimer's disease. The Dimebon program also includes additional trials planned to begin this year in Alzheimer's disease, as well as further development of Dimebon in patients with Huntington's disease. In addition, a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer is ongoing. For more information, please visit us at http://www.medivation.com.
(i) American Cancer Society
Contacts: Medivation, Inc. WeissComm Partners Patrick Machado, Chief Financial Officer Lee-Ann Murphy (415) 829-4101 (415) 946-1088
|SOURCE Medivation, Inc.|
Copyright©2009 PR Newswire.
All rights reserved